Key Highlights

  • Bone Biologics shares printed at USD 0.3601 pre-market on Friday, November 13, 2026, a 10.0% slide, and no company announcement explaining the move has been located.
  • A July 9, 2026 private Placement of 2,112,677 units at USD 1.42 leaves today's price roughly 74.6% under that level, a calculated figure.
  • Warrants issued alongside the placement could Yield around USD 6 million if holders exercise them for cash, meaning potential Supply priced well above the present quote.
  • A summary page of undetermined date mentioned a NELL-1 Patent application and a roughly USD 5 million offering, though neither point was confirmed.

A Sliding Quote Near 35 Cents With No Trigger

Bone Biologics (NASDAQ:BBLG) changed hands at USD 0.3601 ahead of the regular session, a 10.0% loss. Searches of releases, filings and analyst actions dated November 11 to 13, 2026 turned up nothing to explain it. The last price retrieved before today was USD 0.35, updated November 6, 2026, implying the shares have hovered near 35 cents. Such a reading speaks only to this session. At that level, a few trades can shift the figure considerably, spreads may be broad, and a quote can rebound once the normal session is underway. A decline of 10% at this price equates to roughly three and a half US cents.

How the July Placement Warrants Create Potential Supply

The firm is advancing a bone regeneration candidate aimed at spinal fusion, built on the NELL-1 protein. July 9, 2026 brought word of a private placement of 2,112,677 shares or pre-funded warrants at USD 1.42 per unit, each carrying Series F and Series G warrants. Bone Biologics (NASDAQ:BBLG) pegged net proceeds near USD 2.7 million after a 7% placement agent fee and other expenses, and full cash exercise of the warrants could bring roughly USD 6 million. Proceeds are designated for clinical work, including Australian trials, patent upkeep and day-to-day capital. Shares have since dropped well under the placement price. Attaching warrants to a stock sale gives investors extra upside and can produce a continuing stream of shares once those warrants are exercised.

Unverified Offering Plans and the USD 1 Bid Test

A summary page refers to a NELL-1 patent filing and a roughly USD 5 million raise meant to finance trials and enlarge the patent estate. No date or terms were given, the filing was not retrieved, and so both size and price stay unconfirmed. Additional issuance would add to a company whose Market Value is already modest; a published figure of about USD 2.4 million, undated, signals limited valuation. Thirty consecutive trading days below USD 1 can prompt a Nasdaq minimum bid warning, but none has been identified for this company. Runway data was not located. A valuation this small can also come with thin liquidity. Any new raise would therefore land on a Shareholder base that has already been diluted more than once.

Where Things Stand

The decline lacks an announced driver, so it reads as selling pressure on a small company that keeps returning to the market for capital. Bone Biologics (NASDAQ:BBLG) fell 10.0% to USD 0.3601 pre-market, roughly 75% beneath the July placement price. Warrants, a potential USD 5 million raise and a sub-USD 1 quote all raise dilution concerns, while clinical and patent progress represents the longer-term thesis. Watch for offering terms, any listing letter and the next quarterly filing. Quotes at this level are capable of quick reversal.